Back to search

Aristotle University Of Thessaloniki (AUTH)

Ανοσοϊστοχημική διερεύνηση της p53/PUMA κυτταρικής οδού σε ασθενείς με αδενοκαρκίνωμα παχέος εντέρου σταδίου ΙΙ η ΙΙΙ κατά ΤΝΜ

Abstract

dc:description

AIM: The purpose of the study was to investigate, in tumors of patients with colon cancer TNM stage II and III, the immunohistochemical (IHC) expression of a series of protein markers involved in apoptotic PUMA/p53 pathway using the method of tissue microarrays. Additionally we assessed the relationship of the studied indicators with clinicopathological characteristics and with prognosis.MATERIAL AND METHODS: We used paraffin tissue blocks containing tumor, normal tissue and metastatic lymph node from 130 patients with colon cancer stage II and III. We studied by IHC and using the HistoScore the PUMA, p53, Ki-67, BAD, BID, Bcl2 and MDM2 proteins. χ2 or Fisher’s exact tests and Mann-Whitney or Kruskall-Wallis tests were used to test associations between protein expression and different categorical clinicopathological variables. Survival probabilities were estimated by the Kaplan-Meier. For the multivariate analyses of the prognostic markers, model choice was performed using backward selection criteria with P<0.15. RESULTS: 39 patients had cancer in right colon, 52 in left colon and 39 in rectum. In 88 cases administered postoperative chemotherapy. Median follow up time was 54 months (range: 1-81) and the 3-year survival (CSS) was 70.8%. The majority of tumors showed moderate histologic differentiation, 50% was stage B2 (Astler-Coller). Lymphatic invasion detected in 30% of cases, while 50% was free of nodal metastases. Statistically significant correlations emerged between BAD/ BID, PUMA/ BAD, PUMA/ Ki-67 and p53/ MDM2. There was a statistically significant difference in overexpression of BAD, BID, PUMA, Ki-67 and p53 in cancer tissue compared to normal tissue, whereas the Bcl2 expression was higher in normal. Statistically significant associations observed between Bcl-2 and tumor differentiation, BAD and tumor localization, p53 and number of infiltrated lymph nodes, BID/Mdm2 and maximal tumor diameter and Ki-67 with mucinous adenocarcinomas. Smaller CSS, DFS and OS showed patients with lymphatic invasion and ≥4 infiltrated lymph nodes. Worse CSS had patients with poorly differentiated tumor and lower OS, observed in cases who not received chemotherapy, aged ≥ 65 years, stage IIIC AJCC and with right colon cancer. Overexpression of BAD and Ki-67 in IF and PUMA in the TC associated with poor patients’ prognosis. In multivariate analysis as independent unfavorable prognostic indicators for DFS and CSS highlighted the lymphovascular invasion, ≥4 infiltrated lymph nodes and Ki-67 overexpression. Independent adverse predictor for DFS was the overexpression of BAD. For OS emerged as independent adverse prognostic indicators ≥4 metastatic lymph nodes, the location of tumor in rectum and right colon, no chemotherapy treatment and high-expression of p53, Mdm2 and Ki-67. As independent unfavorable prognostic value was highlighted the combination of over-expression of PUMA with low expression of p53 in both OS and CSS.CONCLUSIONS: Significant differences was found in expression of markers between tumor and normal tissue. Significant associations were observed among markers expression and clinicopathological features. In DFS, the high-expression of BAD, and Ki-67, the presence of lymph node metastasis and lymphovascular invasion emerged independent adverse prognostic markers. As independent favorable prognostic indicators for OS were highlighted the lack of lymph node metastasis, the location in the left colon, chemotherapy treatment and low-expression of p53 and Mdm2. The combined high expression of PUMA with low expression of p53, as well as high Ki-67, were independent unfavorable prognostic indicators for both the OS and CSS. Further studies in larger patient cohort are needed to clarify the prognostic role of these markers and to validate the results of our study.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2015

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Mekras, Alexandros
  • Μέκρας, Αλέξανδρος

Subjects

dc:subject × 22

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/35283

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Mekras, Alexandros; Μέκρας, Αλέξανδρος. Ανοσοϊστοχημική διερεύνηση της p53/PUMA κυτταρικής οδού σε ασθενείς με αδενοκαρκίνωμα παχέος εντέρου σταδίου ΙΙ η ΙΙΙ κατά ΤΝΜ. Aristotle University Of Thessaloniki (AUTH), 2015. http://hdl.handle.net/10442/hedi/35283